Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important role

Journal of Medical Virology

Volumn 60, Issue 3, 2000, Pages 249-255

  Steinberg, Joyce L ^a   Yeo, Winnie ^a   Zhong, Sheng ^a   Chan, John Y H ^a   Tam, John S ^a   Chan, Paul K S ^a   Leung, Nancy W Y ^a   Johnson, Philip J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

HBV; Immunosuppressive treatment; Liver disease; Mutant; Reactivation

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FAILURE; POLYMERASE CHAIN REACTION; SOLID TUMOR; VIRUS REACTIVATION;

ADULT; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BREAST NEOPLASMS; CARCINOMA, SMALL CELL; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; FEMALE; GERMINOMA; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE INHIBITORS; TRANS-ACTIVATORS; VIRUS ACTIVATION;

EID: 0033978274     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(200003)60:3<249::AID-JMV1>3.0.CO;2-C     Document Type: Article

References (47)

1. Alexander GJ, Mondelli M, Naumov NV, Nouriaria KT, Vergani D, Lowe D, Eddleston AL, Williams R. 1986. Functional characterization of peripheral blood lymphocytes in chronic HBV carriers. Clin Exp Immunol 63:498-507.
2. Bird GL, Smith H, Portmann B, Alexander GJ, Williams R. 1989. Acute liver decompensation on withdrawal of cytotoxic and immunosuppressive therapy in hepatitis B carriers. Quarterly J Med 73:895-902.
3. Bonino F, Rosina F, Rizzeto M, Rizzi R, Chiaberge E, Tardanico R, Callea F, Verme G. 1986. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastoenterology 90:1268-1273.
4. Brunetto MR, Stemler M, Bonino F, Schodel F, Oliveri F, Rizzetto M, Verme G, Will H. 1990. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol 10: 258-261.
5. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. 1989. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2:588-591.
6. Carman WF, Fagan EA, Hadziyannis S, Karayiannis P, Tassopoulos N C, Williams R, Thomas HC. 1991. Association of a precore genomic variant of HBV with fulminant hepatitis. Hepatology 14: 219-222.
7. Chan HLY, Leung NWY, Hussain M, Wong ML, Lok ASF. 1998. Is precore HBV mutant becoming more prevalent. Hepatology 28 (part 2):484A.
8. Cheng AL. 1996. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma (letter). Blood 87:1202.
9. Chou CK, Wang LH, Lin HM, Chi CW. 1992. Glucocorticoid stimulates hepatitis B viral gene expression in cultured hepatoma cells. Hepatology 16:13-18.
10. Colloredo G, Bellati G, Leandro G, Colombatto P, Rho A, Bissoli F, Brunetto MR. Angeli G, Ideo G, Bonino F. 1996. Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values. J Hepatol 24:644-648.
11. Dienes HP, Gerken G, Georgen B, Heermann K, Gerlich W, Meyer zum Buschenfelde KH. 1995. Analysis of the precore DNA sequence and detection of precore antigen in liver specimens for patients with anti-hepatitis B e-positive chronic hepatitis. Hepatology 21:1-7.
12. Diment JA. 1991. Sensitivity of anti-Hbc IgM kits and the diagnosis of acute hepatitis B. J Clin Pathol 44:438.
13. Duclos-Vallee JC, Laurent-Puig P, Loriot MA, Buffet C, Malka D, Pelletier G, Marcellin P, Erlinger S, Etienne JP. 1994. Fatal reactivation of hepatitis B virus mutant following cytotoxic treatment [letter]. J Hepatol 21:1152.
14. Gaeta GB, Pizzella NT, Russo G, Maisto A, Sardaro C, Galanti B, Giusti G. 1995. Semiquantitative anti-HBc IgM detection in children with chronic hepatitis B: a long term follow-up study. J Med Virol 46:173-177.
15. Galibert F, Mandart E, Fitoussi F, Charnay P. 1979. Nucleotide sequence of the hepatitis B genome (subtype ayw) cloned in E. Coli. Nature 281:646-650.
16. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ, Bagshawe KD. 1975. Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2:528-530.
17. Gan R, Chu M, Shen L, Qian S, Li Z-P. 1987. The complete nucleotide sequence of the cloned DNA of hepatitis B virus subtype adr in pADR. Science in China Series B 30:507-521.
18. Hanson RG, Peters MG, Hoofnagle JH. 1986. Effects of immunosuppressive therapy with prednisolone on B and T cell function in patients with chronic type B hepatitis. Hepatology 6:173-179.
19. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. 1982. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96:447-449.
20. Hong Kong Cancer Registry. 1998. Hospital Authority. Cancer incidence and mortality in Hong Kong 1993-1994.
21. Kosaka Y, Takase K, Kojima M, Shimizu M, Inoue K, Yoshiba M, Tanaka S, Akahane Y, Okamoro H, Tsuda F, Miyakawa Y, Mayumi M. 1991. Fulminant hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology 100:1087-1094.
22. Lau JY, Lai CL, Lin HJ, Lok ASF, Liang RHS, Wu PC, Chan TK, Todd D. 1989. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Quart J Med 73:911-917.
23. Liang RHS, Lok ASF, Lai CL, Chan TK, Todd O, Chiu EKW. 1990. Hepatitis B infection in patients with lymphomas. Hematological One 8:261-270.
24. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. 1991. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182-188.
25. McMillan JS, Bowden DS, Angus PW, McCaughan GW, Locarnini SA. 1996. Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation. Hepatology 24:1371-1378.
26. Milich DR, McLachlan A, Stahl S, Wingfield P, Thornton GB, Hughes JL, Jones JE. 1988. Comparative immunogenicity of hepatitis B virus core and e antigens. J Immunol 141:3617-3624.
27. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. 1990. Is a function of the secreted hepatitis B e antigen to induce immunological tolerance in utero? Proc Nat Acad Sci USA 87: 6599-6603.
28. Mondelli M, Vergani GM, Alberti A, Vergani D, Portmann B, Eddleston ALWF, Williams R. 1982. Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol 129:2273-2278.
29. Moriyama K, Okamoto H, Tsuda F, Mayumi M. 1996. Reduced pre-core transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the pre-core promoter with sequences associated with e antigen-seronegative persistent infections. Virology 226:269-280
30. Mphahlele MJ, Shattock AG, Boner W, Quinn J, McCormick A, Carmen WF. 1997. Trans mission of homogeneous hepatitis B virus population of A 1896-containing strains leading mild resolving acute hepatitis and seroconversion in hepatitis B e antigen in an adult. Hepatology 26:743-746.
31. Naoumov NV, Schneider R, Grotzinger T, Jung MC, Miska S, Pape GR, Will H. 1992. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 102:538-543.
32. Nishizono A, Kohno K, Takita-Sonoda Y, Hiraga M, Terao H, Fujioka T, Nasu M, Mifune K. 1997. Sequential analyses of mutations in the core upstream and precore regions of the hepatitis B virus genome in anti-HBe positive-carriers developing acute exacerbation. J Med Virol 53:266-272.
33. Okamoto H, Tsuda F, Sakugawa H, Sastrosowignjo RI, Imai M, Miyakawa Y, Mayumi M. 1988. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 69:2575-2583.
34. Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M. 1990. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 64:1298-1303.
35. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. 1991. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 324:1699-1704.
36. Pinto PC, Hu E, Bernstein-Singer M, Pinter-Brown L, Govindarajan S. 1990. Acute hepatic injury after withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 65:878-884.
37. Rakela J, Redeker AG, Weliky B. 1983. Effect of short term prednisone therapy on aminotransferase levels and hepatitis B virus markers in chronic type B hepatitis. Gastroenterology 84:956-960.
38. Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K, Tsuda F, Tanaka T, Okamoto H, Miyakawa Y, Mayumi M. 1995. Hepatitis B virus strains in mutations in the core promoter in patients with fulminant hepatitis. Ann Int Med 122;241-248.
39. Scaglioni PP, Melegari M, Wands JR. 1997. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frames. Virology 233:374-381.
40. Scullard GH, Smith CI, Merigan TC, Robinson WS, Gregory PB. 1981. Effects of immunosppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 81:987-991.
41. Soh LT, Ang PT, Sng I, Chua EJ, Ong YW. 1992. Fulminant hepatic failure in non-Hodgkin's lymphoma patients treated with chemotherapy. Eur J Cancer 28A:1338-1339.
42. Thung SN, Gerber MA, Klion F, Gilbert H. 1985. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B carrier. Arch Intern Med 145:1313-1314.
43. Tur-Kaspa R, Klein A, Aharonson S. 1992. Hepatitis B virus precore mutants are identical in carriers for various ethnic origins and are associated with a range of liver disease severity. Hepatology 16: 1338-1342.
44. Uy A, Bruss V, Gerlich WH, Kochel HG, Thomssen R. 1986. Precore sequence of hepatitis B virus inducing e antigen and membrane association of the viral core protein. Virology 155:89-96.
45. Wong GC, Tan P, Goh YT, Ng HS, Lee LH. 1996. Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Ann Acad Med, Singapore 25:500-503.
46. Yen TSB. 1996. Hepadnaviral X protein: review of recent progress. J Biomed Science 3:201996. 30.
47. Yoshiba M, Sekiyama K, Sugata F, Okamoto H, Yamamoto K, Yotsumoto S. 1992. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment. Digest Dis Sci 37:1253-1259.